Genome&Company converts 1,446,248 preferred shares into common stock

Genome&Company converted 1,446,248 convertible preferred shares into common stock on Oct. 7, 2026. Common shares outstanding will rise to 53,747,673 from 52,301,425. The listing of the newly issued common shares is scheduled for Oct. 30, 2026.